MALIGNANT MESOTHELIOMA is an aggressive

Size: px
Start display at page:

Download "MALIGNANT MESOTHELIOMA is an aggressive"

Transcription

1 Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study By M.J. Byrne, J.A. Davidson, A.W. Musk, J. Dewar, G. van Hazel, M. Buck, N.H. de Klerk, and B.W.S. Robinson Purpose: We performed a phase II study of combined cisplatin 100 mg/m 2, given intravenously on day 1, and gemcitabine 1,000 mg/m 2, given intravenously on days 1, 8, and 15 of a 28-day cycle for six cycles among patients with advanced measurable pleural mesothelioma. Patients and Methods: Pleural tumor was measured at three levels on computed tomographic scans at study entry and before the second, fourth, and sixth cycles and every 2 months thereafter to disease progression. Of the 21 patients treated, 19 were male; the median age was 62 years (range, 46 to 74 years); 62% had epithelial tumors; and 18 were classified as tumor-nodemetastasis system stage III or IV. Ninety-four cycles were given (median, six; mean, 4.5 per patient), with a mean relative dose intensity of cisplatin 96.7% and gemcitabine 82.5%. Results: Best objective responses achieved were as follows: complete response, no patients; partial response, 10 patients (complete response partial re- MALIGNANT MESOTHELIOMA is an aggressive tumor of the pleura and peritoneum. It is uncommon but is increasing in incidence, particularly in regions where occupational exposure to asbestos has been prominent. 1 Although it has been the subject of intensive clinical and laboratory research, case fatality for the disease remains high and conventional treatments are inadequate. 2,3 A wide range of chemotherapeutic agents used singly and in combination have been evaluated in the treatment of mesothelioma, but no drugs have consistently induced a response rate of greater than 20%. 3 We have previously reported a phase II evaluation of doxorubicin and interferon alfa-2a in the treatment of patients with mesothelioma and measurable lesions. This regimen yielded a response rate of 16% among 25 patients, with significant toxicity in all patients and no evidence of sustained benefit even among responders. 4 As part of a continuing program to develop and evaluate novel therapies for mesothelioma, we have assessed the antitumor effect of the pyrimidine analog gemcitabine using mesothelioma cell lines of human and murine origin. In a murine mesothelioma model, gemcitabine shows additive antitumor effects when administered in combination with cisplatin and, at clinically achievable concentrations, causes significant tumor regressions. 5 Reports of phase II studies of the use of combined cisplatin and gemcitabine in the treatment of non small-cell lung cancer have been published. 6-8 These indicate an sponse, 47.6% [95% confidence interval, 26.2% to 69.0%]); no change, nine patients; and progressive disease, two patients. Median response duration was 25 weeks, progression-free survival was 25 weeks, and overall survival was 41 weeks. Nine of the 10 responders (90%) and three of nine patients with no change had significant symptom improvement. Serial measurements of vital capacity were performed on three of the responders; all showed a significant increase during the time of remission. Toxicity was mainly gastroenterologic and hematologic. Grade 3 nausea and vomiting occurred in 33% of patients, grade 3 leukopenia in 38%, grade 3 thrombocytopenia in 14%, and grade 4 thrombocytopenia in 19%. Conclusion: Combined cisplatin and gemcitabine is an active combination in malignant mesothelioma and produces symptomatic benefit in responding patients. J Clin Oncol 17: by American Society of Clinical Oncology. acceptable toxicity profile when gemcitabine 1,000 mg/m 2 is administered at weekly intervals on days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m 2 administered as a single dose on day 1, 2, or 15. We report here the results of a phase II study of the efficacy of combined cisplatin and gemcitabine in the treatment of patients with advanced malignant mesothelioma. PATIENTS AND METHODS Patients and Chemotherapy Patients with histologically or cytologically confirmed malignant mesothelioma of the pleura were eligible for entry onto the study. Those included were less than 75 years of age and had measurable disease on thoracic computed tomographic (CT) scans, no prior chemotherapy either systemically or intrapleurally, an Eastern Cooperative Oncology Group performance status of 0 to 2, and a life expectancy of at least 12 weeks. When the disease was confined to the pleural cavity, we demanded that the pleural rind be at least 1.5 cm in thickness, at one From the Departments of Medical Oncology and Respiratory Medicine, Sir Charles Gairdner Hospital; and Departments of Medicine and Public Health, University of Western Australia, Nedlands, Western Australia, Australia. Submitted June 1, 1998; accepted September 28, Address reprint requests to Dr Michael J. Byrne, Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia by American Society of Clinical Oncology X/99/ $3.00/0 Journal of Clinical Oncology, Vol 17, No 1 (January), 1999: pp

2 26 BYRNE ET AL level of the thorax or more, for the disease to be considered measurable. All patients had an adequate bone marrow function (defined as hemoglobin concentration 10 g/dl, total leukocyte count /L, granulocyte count /L, and platelet count /L); adequate renal function (defined as serum creatinine level 120 µmol/l); and adequate hepatic function (defined as total bilirubin level 1.5 times the upper limit of normal and serum ALT and alkaline phosphatase levels 3 times the upper normal limit for the laboratory). Patients were staged using the tumor-node-metastasis system of the International Union Against Cancer. 9 Written informed consent was obtained from each patient before entry. The protocol was approved by the Committee for Human Rights of the University of Western Australia and the Sir Charles Gairdner Hospital Clinical Drug Trials Committee. All patients received cisplatin 100 mg/m 2 intravenously over 1 hour on day 1 and gemcitabine 1,000 mg/m 2 intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. On day 1, cisplatin was administered before gemcitabine. Intensive prophylactic antiemetic therapy with 5-hydroxytryptamine (5-HT 3 ) antagonists and dexamethasone was given intravenously on day 1. Oral 5-HT 3 antagonists and/or phenothiazine antiemetics orally or by suppository were continued over the succeeding 3 to 5 days. On days 8 and 15, gemcitabine was given with 5-HT 3 antagonist cover. In the absence of objective evidence of disease progression, patients were scheduled to receive six cycles of chemotherapy. Dose Adjustments No dose escalations were permitted. A complete blood cell count and differential, serum electrolytes, creatinine, bilirubin, ALT, and alkaline phosphatase levels were assessed on days 1, 8, and 15 of each cycle. The cisplatin dose was reduced to 50% and the gemcitabine dose to 75% if the creatinine level increased to more than 120 µmol/l, and the drugs were delayed or omitted if the creatinine level reached 150 µmol/l. Cisplatin dosage was not adjusted for hematologic toxicity but was delayed on day 1 if gemcitabine was delayed. Gemcitabine dosage was reduced to 75% for a leukocyte count of less than /L or a platelet count of less than /L on day 1, 8, or 15 and was omitted on day 8 or 15 if the leukocyte count was lower than /L or the platelet count lower than /L. Tumor Assessment Clinical history, physical examination, a CT scan of the chest and abdomen, and a chest x-ray were required for all patients before entry. Patients were examined and the chest x-ray was repeated on day 1 of each cycle. A thoracic CT scan was repeated just before day 1 of the second, fourth, and sixth cycles. Patients whose disease was stable or who had achieved a complete or partial response to treatment at the end of six cycles of chemotherapy were observed clinically and given repeat CT scans every 2 months. In all patients with pleural mesothelioma, the thickness of the pleural tumor was measured at three separate levels on transverse sections on the thoracic CT scan at study entry. The sum of the measurements of tumor thickness at the three levels defined a unidimensional measure. Repeat measurements were taken at the same levels at the time of repeat CT scans, and response was assessed by the criteria outlined below. All bidimensionally measurable lesions were measured and used in assessing response. Tumor Response Tumor response was assessed as follows: complete response: complete disappearance of all clinically detectable malignant disease on two occasions at least 4 weeks apart. Partial response: bidimensionally measurable lesions: greater than or equal to a 50% decrease in the sum of the products of the perpendicular diameters of measurable lesions on two occasions at least 4 weeks apart; or unidimensionally measurable lesions: greater than or equal to a 30% decrease in the sum of linear tumor measurements on two occasions at least 4 weeks apart. No change: decrease in size of bidimensionally measurable lesions by less than 50%, or decrease in the size of unidimensionally measurable lesions by less than 30%, or increase in the size of malignant lesions at any site by less than 25%. Progressive disease: bidimensionally or unidimensionally measurable: greater than or equal to a 25% increase in the size of lesions or the appearance of any new lesions. Patients who died of mesothelioma in whom there was no change or a response were regarded as having disease progression at the time of death. Time to disease progression was measured from time of first chemotherapy dose to first date of progression or death. Duration of remission was measured from the first date of best response to date of progression or death. Treatment toxicity was assessed according to World Health Organization criteria. 10 The study was designed to use the one-sample multiple testing procedure of Fleming. 11 The aim was to recruit a maximum of 35 patients with an analysis of the interim results after 15 patients were fully assessable. This plan allowed early termination of the study as soon as possible should it become evident that the true rate of response (complete plus partial responses) was less than 20% or greater than 40%. RESULTS Patient Characteristics The characteristics of the 21 patients entered onto the study are listed in Table 1. Twenty patients had pleural mesothelioma. One patient was ineligible, having peritoneal mesothelioma with no pleural disease, and another had a performance status of 3 at study entry. Because of the requirement for patients to have measurable disease, 18 had stage III or IV disease at the time of entry, and all were symptomatic. Four patients had extrathoracic bidimension- Table 1. Patient and Tumor Characteristics Characteristic No. of Patients Sex Male 19 Female 2 Age, years Median 62 Range Performance status Tumor-node-metastasis system stage I-II 2 III-IV 18 Unstageable (peritoneal) 1 Histologic subtype Epithelial 13 Mixed/biphasic 8 Sarcomatous 0 Prior talc pleurodesis 8

3 CISPLATIN AND GEMCITABINE FOR MESOTHELIOMA 27 ally measurable lesions (supraclavicular nodes and subcutaneous nodules), and four others had similarly measurable intrathoracic lesions. Of the remaining 13 patients, 12 had pleural lesions that were unidimensionally measurable but had no bidimensionally measurable lesions, and one had a peritoneal mesothelioma, which was not measurable. Response to Treatment A total of 94 cycles of treatment were delivered to the 21 patients. The median number of cycles per patient was six (mean, 4.5 cycles). The relative dose intensity of treatment delivered was high for both cisplatin (median, 100%; mean, 96.7%) and gemcitabine (median, 91%; mean, 82.5%) and was similar for responders and for the group as a whole. Eleven patients completed the scheduled six cycles of treatment. Of those who did not complete six cycles, seven patients had disease progression while on treatment, and two refused further therapy after the first cycle of treatment because of gastrointestinal toxicity. Another patient, who had stable disease after three cycles of treatment, ceased chemotherapy because of an unrelated intercurrent illness. His disease progressed 7 months later, and he then received a further three cycles. The data on treatment response are listed in Table 2. No patient had a complete remission of disease. Ten patients had a partial response, and in nine, the best response achieved was no change. In two patients, the disease progressed without a period of prior stabilization. The overall response rate was 47.6% (95% confidence interval [CI], 26.2% to 69%). For those with pleural mesothelioma, the overall response rate was 50%. In nine of the 10 responding patients, the mesothelioma was of the epithelial subtype; one patient had a mixed or biphasic tumor. A response was observed among nine (69%) of 13 patients with measurable disease and epithelial mesothelioma and among one (14%) of seven with biphasic mesotheliomas. The patient with peritoneal mesothelioma (not measurable) had a biphasic tumor. Among those achieving a partial remission, the median duration of response was 25 weeks (range, 8 to 33 weeks). Symptom Control Formal quality-of-life assessment was not performed in this study; however, serial changes in symptoms were noted after chemotherapy administration. No patient was asymptomatic at the time of treatment. Seventeen complained of shortness of breath, 13 of chest wall, shoulder, or arm pain, three of lethargy, two of cough, two of anorexia, and one each of night sweats and nausea. Nine of the 10 responding patients had substantial or complete relief of symptoms. The remaining patient had been dyspneic on study entry and remained so. Three other patients, who had stable disease on objective assessment, gained significant symptomatic benefit from treatment. Serial measurements of vital capacity were recorded for three of the responding patients and showed significant improvement correlating with the objective changes on CT scans. Re-treatment Five patients were retreated after progression had occurred after cessation of the initial therapy. Four patients had had a partial remission of disease with the initial six cycles of treatment, and one patient, whose disease was stable after three cycles, progressed after a treatment break due to an unrelated intercurrent illness. None of these patients achieved a partial response on retreatment; five had stable disease accompanied by transient symptomatic improvement lasting 4 to 12 weeks. Disease Progression and Relapse Mesothelioma progressed in 19 of the 21 patients after treatment. The median progression-free survival for the total group was 25 weeks (95% CI, 17 to 33 weeks). For the 10 patients who achieved a partial remission of disease, the median time to progression was 36 weeks (95% CI, 28 to 44 weeks). For those in whom the disease stabilized on treatment, the median time to progression was 22 weeks (95% CI, 5 to 39 weeks). Response Category Table 2. Response to Treatment No. of Patients Complete response 0 Partial response 10 No change 9 Progressive disease 2 Total response* (%) 10 (47.6) Total 21 *Complete response partial response. Survival The estimated median survival for the whole group was 41 weeks (95% CI, 24 to 59 weeks), with an estimated 1-year survival of 41%. The distribution of progression-free survival times and survival are shown in Fig 1. Survival from the time of initial diagnosis of malignant mesothelioma for the group as a whole was 56 weeks (95% CI, 13 to 99 weeks).

4 28 BYRNE ET AL Fig 1. Progression-free survival (PFS) and overall survival (OS) for all patients from start of cisplatin-gemcitabine treatment. Toxicity The major toxicities observed were gastrointestinal and hematologic (Tables 3 and 4). Severe nausea and vomiting was experienced on at least one occasion by one third of patients and was worst after day 1 of treatment. Approximately 50% vomited with at least one cycle. Day 8 and 15 gemcitabine treatment rarely caused vomiting. Thrombocytopenia on day 8 or 15 was the major cause of dose modification. No patient had bruising or bleeding. One patient required treatment for febrile neutropenia. Significant cumulative hematologic toxicity was not demonstrated. Hospitalization was required on three occasions for control of nausea and vomiting, once for febrile neutropenia, and once for unexplained abdominal pain. Table 3. Treatment Toxicity Among 21 Patients Worst Toxicity Grade (% of patients) Leukopenia Thrombocytopenia Anemia Nausea/vomiting Diarrhea Stomatitis Alopecia Hearing loss Neurologic DISCUSSION The cisplatin and gemcitabine regimen used in this trial produced a 47% objective response rate in patients with advanced malignant mesothelioma. This exceeds the response seen in our previous trial of adriamycin and interferon alfa in similar patients. The high response rate observed in this study suggests that the combination of cisplatin and gemcitabine may have greater efficacy than most other single agents or combinations. In a recent review of studies that accrued more than 15 patients, Ong and Vogelzang 3 found no drug that consistently induced a response in greater than 20% of patients with mesothelioma. Higher response rates to detorubicin (26%), high-dose methotrexate (37%), and edatrexate (25%), reported in single phase II studies, have yet to be confirmed Neither cisplatin, 15,16 with a response rate of 13% to 14%, nor gemcitabine, with a response rate of 0% to 31%, has shown great promise as a single agent, although the response rate to the latter has been variable. Table 4. Risk of Developing Grade 3 or 4 Hematologic Toxicity by Cycle Cycle (no. of patients) Patients At risk With leukopenia With thrombocytopenia

5 CISPLATIN AND GEMCITABINE FOR MESOTHELIOMA 29 Regimens involving combinations of agents have been similarly disappointing with three exceptions. Breau et al 20 reported a response rate of 44% among patients with stage II and III mesothelioma given a combination of cisplatin, adriamycin, bleomycin, and mitomycin C plus systemic and intrapleural hyaluronidase. This study apparently has yet to be published in full. Trandafir et al 21 observed a response rate of 36% among 22 patients with predominantly stage II and III mesothelioma to a combination of cisplatin and low-dose interferon alfa. Middleton et al, 22 using a combination of mitomycin C, vinblastine, and cisplatin, achieved a 32% objective response rate among 22 patients, 59% of whom gained significant symptomatic relief with the treatment. Our data indicate that cisplatin and gemcitabine, used in the dose and schedule described, are clearly an active combination in the treatment of patients with advanced mesothelioma. Although quality of life was not formally measured in this patient group, all patients were symptomatic at the time of entry into the study. Significant symptomatic improvement occurred in approximately 90% of those in whom the disease showed an objective response and in a number in whom a no-change status was achieved. Decrease or cessation of chest pain was frequently reported and often accompanied by an increase in exercise tolerance and a decrease in dyspnea. Subjective improvement was also reported in a number of patients who were retreated after a further disease progression, although objective improvement was less clear. The symptomatic improvement seen in patients on this regimen is in sharp contrast to the results experienced by patients receiving adriamycin and interferon alfa in our earlier trial. In that study, we found little evidence of overall subjective benefit, even among those who achieved an objective response. Even with the use of serial CT scans, malignant mesothelioma is difficult to measure. When the disease was confined to the pleural cavity, we demanded that the pleural rind be at least 1.5 cm in thickness, at one level of the thorax or more, for the disease to be considered measurable. We assessed thickness at three levels on the CT scan and used the sum of the measurements of thickness at reproducible points to compute a unidimensional measurement. A decrease of 30% in this measurement, sustained for at least 4 weeks, was required to confirm a partial tumor response. If patients had bidimensionally measurable lesions, these were measured and a 50% decrease in the sum of the products of the diameters of the lesions was used to define a partial response. Although these criteria have not been validated in mesothelioma, and there are no validated response criteria for the disease, three of our patients who achieved a response showed a measured and significant increase in vital capacity. In addition, responding patients lived longer than nonresponding patients. These observations suggest that the response criteria used define tumor regression of sufficient magnitude to be of practical benefit to the patient. A larger experience will be necessary to confirm these observations and to validate the criteria. Malignant mesothelioma is a disease in which there is no standard treatment. Criteria for the assessment of objective response are not standardized and have not been correlated with functional or symptomatic benefit. The combination of cisplatin and gemcitabine seems promising. If the results obtained in this single-institution study can be repeated and reproduced in a multicenter setting, the combination may constitute an advance over best supportive care, but this would need evaluation in a randomized comparison with quality-of-life end points. 1. Musk AW, Dolin PJ, Armstrong BK, et al: The incidence of malignant mesothelioma in Australia, Med J Aust 150: , Musk AW, Woodward SD: Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust N Z J Med 12: , Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 14: , Upham J, Musk AW, van Hazel G, et al: Interferon alfa and doxorubicin in malignant mesothelioma: A phase II study. Aust N Z J Med 23: , Davidson JA, Robinson BWS: Gemcitabine activity on murine and human malignant mesothelioma cell lines show additive activity in combination with cisplatin. Aust N Z J Med 27:213, Sandler A, Ansari R, McClean J, et al: Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study. Eur J Cancer 31A:S225, 1995 (suppl 5, abstr 1079) REFERENCES 7. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-smallcell lung cancer. J Clin Oncol 15: , Crino L, Seagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15: , Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumours (ed 4, revision 2). Berlin, Germany, Springer-Verlag, Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: , Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: , Colbert N, Vannetzel JM, Izrael V, et al: A prospective study of detorubicin in malignant mesothelioma. Cancer 56: , Solheim OP, Saeter G, Finnanger AM, et al: High dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 65: , 1992

6 30 BYRNE ET AL 14. Belani CP, Herdon J, Vogelzang NJ, et al: Edatrexate for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9131). Proc Am Soc Clin Oncol 13:329, 1994 (abstr) 15. Mintzer DM, Kelsen D, Frimmer D: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69: , Zidar BL, Green S, Pierce HI, et al: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6: , Van Meerbeeck JP, Baas P, Debruyne C, et al: Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study. Lung Cancer 18:17, 1997 (suppl 1) 18. Millard FE, Herndon J, Vogelzang MR, et al: Gemcitabine for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9530). Proc Am Soc Clin Oncol 16:1710, Bischoff HG, Manegold C, Knopp M, et al: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:1784, Breau JL, Boaziz C, Morere JJF, et al: Combination chemotherapy with cisplatinum, adriamycin, bleomycin and mitomycin C plus systemic and intrapleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesothelioma. First International Mesothelioma Conference, Paris, France, 1991 (abstr 15) 21. Trandafir L, Borel C, Ruffie P, et al: Combined systemic CDDP-interferon alfa (IFN) in advanced pleural malignant mesothelioma. Proc Am Soc Clin Oncol 13:405, Middleton GW, Verrill MW, Priest K, et al: Good symptom relief with palliative MVP (mitomycin C, vinblastine, cisplatin) chemotherapy in malignant mesothelioma. Lung Cancer 18:22, 1997 (suppl 1)

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Kasr El-Aini Center of Clinical Oncology, Faculty of medicine, 2 Chest Department, Faculty of medicine, Cairo University, egypt

Kasr El-Aini Center of Clinical Oncology, Faculty of medicine, 2 Chest Department, Faculty of medicine, Cairo University, egypt Kasr El-aini J. Clin. Oncol. nucl. med. vol., no. 3-4, Jul.-oct. 006:4-47 NEMROCK Original Article Phase II Trial of Cisplatin and Vinorelbine as First-line Therapy in Malignant Pleural Mesothelioma Salah

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Annals of Oncology 9: 9-7, 998. 998 Khmer Academic Publishers. Printed in the Netherlands Original article Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

J Clin Oncol 24:3007-3012. 2006 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24:3007-3012. 2006 by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma

More information

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma British Journal of Cancer (2) 87, 491 496 ª 2 Cancer Research UK All rights reserved 7 9/2 $25. www.bjcancer.com A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma AK

More information

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200 GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Summary & Conclusion

Summary & Conclusion The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

New Evaluation Criteria for Response and Toxicity in Lung Cancer Treatment

New Evaluation Criteria for Response and Toxicity in Lung Cancer Treatment Lung Cancer New Evaluation Criteria for Response and Toxicity in Lung Cancer Treatment JMAJ 46(12): 554 558, 2003 Masahiko SHIBUYA Chief, Division of Respiratory Medicine, Tokyo Metropolitan Komagome Hospital

More information

Lessons learned from the Western Australian experience with mesothelioma

Lessons learned from the Western Australian experience with mesothelioma Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Sonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995

Sonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995 Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,

More information

HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1

HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all

More information

Clinical Study Report

Clinical Study Report An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Second-Line Chemotherapy

Second-Line Chemotherapy 40 Second-Line Chemotherapy Nick Pavlakis and Nicholas J. Vogelzang Chemotherapy trials for malignant pleural mesothelioma have almost exclusively focused on chemotherapy-naive patients. Until 2000, the

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen

More information

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 1, March: 61-70, 2007 Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

MALIGNANT PLEURAL mesothelioma (MPM) is a locally

MALIGNANT PLEURAL mesothelioma (MPM) is a locally Phase III Study of Pemetrexed in Combination With Versus Alone in Patients With Malignant Pleural Mesothelioma By Nicholas J. Vogelzang, James J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel,

More information

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Exploring the Role of Vitamins in Achieving a Healthy Heart

Exploring the Role of Vitamins in Achieving a Healthy Heart Exploring the Role of Vitamins in Achieving a Healthy Heart There are many avenues you can take to keep your heart healthy. The first step you should take is to have a medical professional evaluate the

More information

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. 1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300

More information

Archive of SID. www.sid.ir

Archive of SID. www.sid.ir Response, tolerability and toxicity of new chemotherapeutic ORIGINAL regimen in advanced ARTICLE Gastric Ca Evaluation of Response, Tolerability and Toxicity of New Chemotherapeutic Regimen in Advanced

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Report on New Patented Drugs - Alimta

Report on New Patented Drugs - Alimta Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

SECOND-LINE CHEMOTHERAPY in advanced non

SECOND-LINE CHEMOTHERAPY in advanced non Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

ARTICLE IN PRESS. European Journal of Radiology xxx (2009) xxx xxx. Contents lists available at ScienceDirect. European Journal of Radiology

ARTICLE IN PRESS. European Journal of Radiology xxx (2009) xxx xxx. Contents lists available at ScienceDirect. European Journal of Radiology European Journal of Radiology xxx (2009) xxx xxx Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Three-dimensional evaluation of

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

TOXIC EFFECTS OF CHEMOTHERAPY, IMMUNOTHERAPY AND CHEMOIMMUNOTHERAPY IN PATIENTS WITH CUTANEOUS MELANOMA

TOXIC EFFECTS OF CHEMOTHERAPY, IMMUNOTHERAPY AND CHEMOIMMUNOTHERAPY IN PATIENTS WITH CUTANEOUS MELANOMA 2014 TOXIC EFFECTS OF CHEMOTHERAPY, IMMUNOTHERAPY AND CHEMOIMMUNOTHERAPY IN PATIENTS WITH CUTANEOUS MELANOMA * Oradea University, Faculty of Medicine and Pharmacy, 10 Decembrie 1 St St., Oradea, Romania,

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total

More information

The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992)

The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992) European Journal of Cancer 39(2003) 353 357 www.ejconline.com The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992) P. Baas a, *, A. Ardizzoni b, F.

More information

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

MALIGNANT MESOTHELIOMA is a tumor of the pleura

MALIGNANT MESOTHELIOMA is a tumor of the pleura Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study By K. Fizazi, H. Doubre, T. Le Chevalier, A. Riviere, J. Viala, C. Daniel, L. Robert,

More information

Canine Lymphoma Frequently Asked Questions by Pet Owners

Canine Lymphoma Frequently Asked Questions by Pet Owners Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes

More information

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is

More information

Asbestos Health Risks. Dr Andrew Pengilley Acting Chief Health Officer

Asbestos Health Risks. Dr Andrew Pengilley Acting Chief Health Officer Asbestos Health Risks Dr Andrew Pengilley Acting Chief Health Officer Asbestos Asbestos is a name given to several different fibrous minerals Three main commercial types are Chrysotile (white asbestos)

More information

J Clin Oncol 26:3567-3572. 2008 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26:3567-3572. 2008 by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 21 JULY 20 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1 Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this

More information

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer CLINICAL STUDY Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer Ahmet Bircan, MD 1 ; M. Bahad r Berktafl, MD 1 ; Hülya Bay z, MD 1 ; Nihal Baflay, MD 1 ; Sema Bircan, MD 2 ; Mine

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors

Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada

Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Erich Kliewer Alain Demers Sri Navaratnam Coreen Hildebrand Grace Musto Report for AstraZeneca

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information